Creative Medical Technology Holdings Shares Up After Agreement with University of Miami to Accelerate Development of ImmCelz®

Mar 31, 2022 By MarketDepth

Biotechnology Healthcare Investing What's Hot

Cancer Research test tube

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) shares up more than 20% Thursday after the medical Company announced that it has signed a Master Collaboration Agreement with the University of Miami to accelerate development of the Company’s ImmCelz® Supercharged Autologous Immunotherapy Platform.

Patent Protected Stem Cell

ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient’s immune cells. After the patient’s harvested cells are incubated with the Company’s cell-free reprogramming “cocktail”, the cells are re-injected back into the patient.

“This valuable partnership with the University of Miami accelerates the development of our ImmCelz® platform. Under the leadership of Drs. Camillo Ricordi and Giacomo Lanzoni at the cGMP Advanced Human Cell and Biologics Manufacturing Facility of the Cell Transplant Center at the Diabetes Research Institute, University of Miami Miller School of Medicine, we will continue to optimize the platform and generate data required to advance our therapies through clinical trials.”

Timothy Warbington, President and CEO of the Company

“Dr. Lanzoni and I are excited to expand our relationship with Tim and the Creative Medical Technology leadership team to further the advancement of the ImmCelz® platform,” said Dr. Ricordi. “As previously announced, we already have seen early success, suggesting the ability of ImmCelz® to achieve superior results in a pre-clinical, in-vitro model system that should be amenable to safe, scalable and rapid clinical translation.”

“For integration in this Master Collaboration Agreement, a project proposal and research budget were submitted from the team at the University of Miami and accepted by the Company with the goal to begin additional research immediately. It is our intent to disclose relevant results when appropriate.”

Timothy Warbington, President and CEO of the Company